June 13, 2019 / 5:15 AM / 2 months ago

BRIEF-Roche: Rituximab Phase III Study Met Primary Endpoint

June 13 (Reuters) - Roche Holding AG:

* PHASE III PEMPHIX STUDY SHOWED THAT MABTHERA/RITUXAN (RITUXIMAB) IS SUPERIOR TO STANDARD OF CARE IN ACHIEVING SUSTAINED REMISSION IN PATIENTS WITH PEMPHIGUS VULGARIS

* MABTHERA/RITUXAN MET THE PRIMARY AND SECONDARY ENDPOINTS IN THE PHASE III PEMPHIX STUDY

* LATEST PHASE IIISTUDY MET THE PRIMARY ENDPOINT, AND DEMONSTRATED THAT MABTHERA IS SUPERIOR TO MMF IN ACHIEVING SUSTAINED COMPLETE REMISSION Source text: [bit.ly/2RcXDKD] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below